A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn’t yet shown the health impacts of cycling on and off the drugs.
obesity treatments
Posted inNPR
The FDA approves a new obesity pill, giving patients another option
The daily pill called Foundayo got a fast track through the Food and Drug Administration. It will compete with the pill form of Wegovy as an alternative to obesity drugs given by injection.
Posted inNPR
GLP-1 drugs don’t work for everyone. But personalized obesity care in the future might
As doctors learn why GLP-1s don’t work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now.
Posted inNPR
Wegovy obesity pill now available at pharmacies
Drugmaker Novo Nordisk said the prescription medicine can be found at a range of pharmacies, including CVS and Costco, as well as some telehealth providers.
Posted inNPR
Decades-old law limits access to Wegovy for Medicaid beneficiaries
New medications like Wegovy are changing the way people lose weight and manage obesity, but many Medicaid beneficiaries can’t get them.
